These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 17017544)

  • 1. Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies.
    Németh H; Toldi J; Vécsei L
    J Neural Transm Suppl; 2006; (70):285-304. PubMed ID: 17017544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of kynurenines in the central and peripheral nervous systems.
    Németh H; Toldi J; Vécsei L
    Curr Neurovasc Res; 2005 Jul; 2(3):249-60. PubMed ID: 16181118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
    Tan L; Yu JT; Tan L
    J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
    Ostapiuk A; Urbanska EM
    CNS Neurosci Ther; 2022 Jan; 28(1):19-35. PubMed ID: 34862742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
    Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
    Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
    Sas K; Robotka H; Toldi J; Vécsei L
    J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of [5-(3)H]kynurenine in the developing rat brain in vivo: effect of intrastriatal ibotenate injections.
    Ceresoli G; Guidetti P; Schwarcz R
    Brain Res Dev Brain Res; 1997 May; 100(1):73-81. PubMed ID: 9174248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo assessment of kynurenate neuroprotective potency and quinolinate excitotoxicity.
    Obrenovitch TP; Urenjak J
    Amino Acids; 2000; 19(1):299-309. PubMed ID: 11026501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
    Sapko MT; Guidetti P; Yu P; Tagle DA; Pellicciari R; Schwarcz R
    Exp Neurol; 2006 Jan; 197(1):31-40. PubMed ID: 16099455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications.
    Füvesi J; Rajda C; Bencsik K; Toldi J; Vécsei L
    J Neural Transm (Vienna); 2012 Feb; 119(2):225-34. PubMed ID: 22258797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients.
    Heyes MP; Brew BJ; Saito K; Quearry BJ; Price RW; Lee K; Bhalla RB; Der M; Markey SP
    J Neuroimmunol; 1992 Sep; 40(1):71-80. PubMed ID: 1387655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease.
    Lim CK; Fernández-Gomez FJ; Braidy N; Estrada C; Costa C; Costa S; Bessede A; Fernandez-Villalba E; Zinger A; Herrero MT; Guillemin GJ
    Prog Neurobiol; 2017 Aug; 155():76-95. PubMed ID: 27072742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum kynurenic acid is reduced in affective psychosis.
    Wurfel BE; Drevets WC; Bliss SA; McMillin JR; Suzuki H; Ford BN; Morris HM; Teague TK; Dantzer R; Savitz JB
    Transl Psychiatry; 2017 May; 7(5):e1115. PubMed ID: 28463241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the treatment of amyotrophic lateral sclerosis. Emphasis on kynurenine pathway inhibitors.
    Chen Y; Meininger V; Guillemin GJ
    Cent Nerv Syst Agents Med Chem; 2009 Mar; 9(1):32-9. PubMed ID: 20021336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kynurenic acid antagonists and kynurenine pathway inhibitors.
    Stone TW
    Expert Opin Investig Drugs; 2001 Apr; 10(4):633-45. PubMed ID: 11281814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tryptophan, adenosine, neurodegeneration and neuroprotection.
    Stone TW; Forrest CM; Mackay GM; Stoy N; Darlington LG
    Metab Brain Dis; 2007 Dec; 22(3-4):337-52. PubMed ID: 17712616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
    Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
    Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Tryptophan Dysmetabolism and Quinolinic Acid in Depressive and Neurodegenerative Diseases.
    Hestad K; Alexander J; Rootwelt H; Aaseth JO
    Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kynurenic Acid Restores Nrf2 Levels and Prevents Quinolinic Acid-Induced Toxicity in Rat Striatal Slices.
    Ferreira FS; Biasibetti-Brendler H; Pierozan P; Schmitz F; Bertó CG; Prezzi CA; Manfredini V; Wyse ATS
    Mol Neurobiol; 2018 Nov; 55(11):8538-8549. PubMed ID: 29564809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection.
    Vamos E; Pardutz A; Klivenyi P; Toldi J; Vecsei L
    J Neurol Sci; 2009 Aug; 283(1-2):21-7. PubMed ID: 19268309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.